Clinical trial NCT02129309: Haemodynamic Effects of Apelin Agonists and Antagonists in Man in COPD With Raised Pulmonary Artery Pressures
Official title: Haemodynamic Effects of Apelin Agonists and Antagonists in Man in COPD With Raised Pulmonary Artery Pressures.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COPD
Pulmonary Hypertension
Keywords: COPD
Apelin
agonist
antagonist
Lead sponsor: Cambridge University Hospitals NHS Foundation Trust
Sponsor class: OTHER
Collaborators: name: Wellcome Trust
name: University of Cambridge
First posted: 2014-05-02
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The investigators are interested in studying how Pulmonary Hypertension occurs. A substance called 'apelin', that naturally occurs in the body has been shown to have an important role in heart disease. Previous studies have shown that it can make blood vessels get wider, and help blood flow around the body and thus improve the way the heart and lungs work.

The investigators are looking to recruit both healthy and COPD pulmonary hypertension patients to study 3 types of apelin. The purpose of this study is to help the investigators understand how Pulmonary Hypertension occurs which may will help with the development of future treatments.

Detailed description: The purpose of this study:

To investigate the physiological role of apelin in the cardiovascular system in patients with COPD with raised pulmonary artery pressures.

Study Aim and hypotheses:

The primary objective is to test the above hypotheses using forearm blood flow and systemic infusions of apelin peptides.

Hypotheses:

1. Apelin agonists are vasodilators in human resistance vessels and this effect will be altered in patients with pulmonary hypertension.
2. Apelin peptides improve right ventricular and pulmonary haemodynamics in patients with elevated pulmonary artery pressures.

Study 1a - A validation dose study of 3 apelin agonists performed in healthy volunteers and COPD patients with elevated pulmonary artery pressures.

Study 1b- A validation dose study of apelin receptor antagonist, in healthy volunteers and COPD patients with elevated pulmonary artery pressures.

Study 2a - To define the haemodynamic response to apelin agonists in healthy volunteers and evaluate the response.

Study 2b - To investigate the haemodynamic response to 3 apelin agonists in COPD patients with elevated pulmonary artery pressures.

Eligibility criteria: Inclusion Criteria:

* Healthy volunteers

  * Aged 18 to 70 years
  * Non-smoker (\<1 cigarette per week)
  * If female, postmenopausal or on days 2-9 of menstrual cycle and negative pregnancy test COPD patients with estimated Pulmonary Artery Pressure (PAP) on echo \>25mmHg
  * Clinical diagnosis of COPD as per standard criteria
  * Between 18 and 70 years
  * If female, postmenopausal or on days 2-9 of menstrual cycle and negative pregnancy test

Exclusion Criteria:

* pre-existing:

  * Systemic Hypertension (sustained BP \>160/100mmHg)
  * Ischaemic Heart Disease
  * Primary valvular heart disease
  * Significant left ventricular failure
  * Active malignancy
  * Renal disease (Creatinine \>180 µmol/L)
  * Neurological disease
  * Diabetes mellitus
  * BMI \>35, BMI \<17
  * Pregnancy
  * Use of vasoactive medication or NSAIDS/aspirin within 48 hours of study.
  * Current involvement in other research studies, other than observational/non-interventional
  * Known HIV

Primary outcomes:
measure: Percentage change in forearm blood flow in the infused arm. Forearm blood flow ratio in each arm, blood pressure and heart rate will also be reported.
timeFrame: 12 months
measure: Cardiac output and stroke volume, pulmonary vascular resistance, mean arterial pressure and heart rate.
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
measure: Exploratory endpoints in Study 2 are systolic and diastolic blood pressure.
timeFrame: 12 months
Locations:
city: Cambridge
country: United Kingdom
facility: Vascular Research Unit, Clinical Pharmacology Unit, ACCI, Level 3, Addenbrooke's Hospital, Hills Road
Study officials:
affiliation: Cambridge University Hospitals NHS Foundation Trust
name: Dr. Joseph Cheriyan, MD
role: PRINCIPAL_INVESTIGATOR
References: